Chen Yu, TCGX founder and managing partner
January 4, 2024 08:00 AM EST
Financing
Bioregnum

As the biotech fund­ing game changed, TCGX al­tered course — and now they’re back with $1B for round two

John Carroll

Editor & Founder

When Chen Yu and his team at TCGX set out in ear­ly 2021 with some $800 mil­lion to in­vest in biotech, he …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times